Acura Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing formulations that address abuse, misuse and overdose of opioid pain medications, as well as innovative over-the-counter therapies. The company’s core mission is to enhance patient safety and deter drug abuse through advanced formulation technologies, positioning itself at the intersection of public health and pain management.
Among Acura’s portfolio are abuse-deterrent prescription products such as Oxaydo®, an immediate-release oxycodone solution designed to resist crushing and extraction for non-oral abuse, and ARYMO® ER, an extended-release morphine sulfate tablet formulated to reduce potential for tampering. In the over-the-counter channel, Acura markets Nexafed®, a pseudoephedrine product engineered to deter illicit methamphetamine production, and Vazalore®, a unique soluble aspirin softgel aimed at enhancing cardiovascular therapeutic absorption.
Founded in 1993 and headquartered in Palatine, Illinois, Acura has advanced its product candidates through multiple FDA approvals and regulatory milestones. The company leverages strategic licensing agreements and distribution partnerships to bring its products to pharmacies and healthcare providers across the United States, with a focus on maximizing patient access while maintaining rigorous safety standards.
Under the leadership of President and Chief Executive Officer Kenneth P. Moch, Acura’s management team combines expertise in pharmaceutical development, regulatory affairs and capital markets. The board and executive officers draw upon decades of industry experience to drive innovation in drug formulation and uphold the company’s commitment to harm reduction and patient care.
AI Generated. May Contain Errors.
